Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
RNAC on Nasdaq
Shares outstanding
25,792,245
Price per share
$7.66
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,770,039
Total reported value
$19,969,029
% of total 13F portfolios
0%
Share change
-83,998
Value change
-$2,400,039
Number of holders
40
Price from insider filings
$7.66
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SPRINGER TIMOTHY A 37% +0.27% $116,671,361 +$258,583 9,555,394 +0.22% Timothy A. Springer 13 Jan 2025
JPMORGAN CHASE & CO 6.1% $20,459,516 1,675,636 JPMORGAN CHASE & CO. 31 Mar 2025
FMR LLC 5.3% -38% $9,869,661 -$5,695,093 1,366,989 -37% FMR LLC 31 Dec 2025

As of 31 Dec 2025, 40 institutional investors reported holding 2,770,039 shares of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC). This represents 11% of the company’s total 25,792,245 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) together control 11% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 2.4% 609,696 -6.1% 0% $4,395,908
VANGUARD GROUP INC 2.1% 541,228 +3.9% 0% $3,902,253
Erste Asset Management GmbH 1.1% 271,705 +4.5% 0.02% $1,956,354
GEODE CAPITAL MANAGEMENT, LLC 0.99% 255,539 +5.7% 0% $1,842,696
STATE STREET CORP 0.77% 198,967 +0.66% 0% $1,434,552
MARSHALL WACE, LLP 0.69% 178,140 +110% 0% $1,284,388
Privium Fund Management B.V. 0.67% 172,500 0.23% $1,243,725
JACOBS LEVY EQUITY MANAGEMENT, INC 0.37% 95,799 +219% 0% $690,711
GSA CAPITAL PARTNERS LLP 0.3% 77,227 -10% 0.05% $557,000
UBS Group AG 0.26% 67,341 +577% 0% $485,528
Walleye Capital LLC 0.17% 43,878 0% $316,360
RENAISSANCE TECHNOLOGIES LLC 0.16% 41,100 0% $296,331
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.1% 25,300 +1.6% 0% $182,413
Bank of New York Mellon Corp 0.1% 25,241 +4.3% 0% $181,988
Nuveen, LLC 0.09% 24,497 0% 0% $176,623
MORGAN STANLEY 0.09% 23,294 +23% 0% $167,950
Squarepoint Ops LLC 0.07% 18,213 0% $131,316
BARCLAYS PLC 0.07% 17,651 -1.1% 0% $127,264
Miller Financial Services LLC 0.05% 13,643 +17% 0.12% $98,366
RHUMBLINE ADVISERS 0.05% 12,139 -7.6% 0% $87,515
WELLS FARGO & COMPANY/MN 0.05% 11,762 +49% 0% $84,804
R Squared Ltd 0.04% 10,308 0.03% $74,321
DEUTSCHE BANK AG\ 0.03% 8,112 +9.3% 0% $58,488
AlphaQuest LLC 0.03% 6,924 0% 0% $49,922
JPMORGAN CHASE & CO 0.02% 5,889 -3.8% 0% $42,460

Institutional Holders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,770,039 $19,969,029 -$2,400,039 $7.21 40
2025 Q3 5,968,086 $60,898,831 -$4,440,064 $10.22 65
2025 Q2 6,401,037 $66,468,780 -$2,049,017 $10.39 65
2025 Q1 6,582,077 $86,710,172 -$755,346 $13.18 68
2024 Q4 6,665,799 $119,478,509 -$2,692,613 $17.91 64
2024 Q3 6,867,968 $110,349,366 +$42,879,892 $16.12 61
2024 Q2 3,268,033 $88,276,427 +$88,059,260 $27.01 57
2024 Q1 1,855 $1,157 +$1,157 $0.64 4
2023 Q4 0 $0 -$1,272 $7.66 0
2023 Q3 1,200 $1,272 $1.06 1
2023 Q2 1,200 $1,344 $1.12 1
2023 Q1 1,200 $1,668 +$1,668 $1.39 1